Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials

Do you leverage a quality-first mindset as you evaluate clinical trial technology? When you evaluate eCOA and IRT solutions, quality cannot be ignored, as choosing poorly can lead to data integrity issues, regulatory roadblocks, and costly delays that can postpone potentially lifesaving treatments. How can you ensure your clinical trial technology partner prioritizes quality throughout the clinical research journey? This checklist is your guide to choosing a quality-first solution.

As drug development costs continue to escalate, sponsors are incentivized to find less expensive approaches to develop their assets. FSP models provide increased operational and resourcing flexibility and different pricing plans in comparison to traditional full-service CRO offerings.

Large CROs operate with a one-size-fits-all approach. When this no longer worked for a late-stage clinical biopharmaceutical company, they turned to Catalyst Flex to design a tailored solution to meet the safety needs of this rescue study.

Speed is critical in clinical drug development. With a strong pool of resources, Catalyst Flex is able to efficiently and effectively resource studies. Learn more about this rapid rescue transition to deploy clinical research associates (CRAs) to 95 clinical sites within weeks.

This article explores the strategic importance of FSPs in clinical research, emphasizing their contributions to cost efficiencies, the acceleration of drug development, and technological innovation in trial management. Learn how FSPs provide numerous advantages.